CoChat

Suprachoroidal gene transfer with nonviral nanoparticles

Open access

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Suprachoroidal gene transfer with nonviral nanoparticles provides noninvasive transgene expression in photoreceptors and RPE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.aba1606

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Polymer structure and NP characterization. (A) Cationic 1-(3-aminopropyl)-4-methyl-piperazine endcapped poly(1,4-butanediol-diacrylate-co-5-amino-1-pentanol) (named PBAE 457) is used to electrostatically self-assemble with plasmid DNA (pDNA) to form nonviral gene delivery NPs. (B) Hydrodynamic diameter and zeta potential of 457/DNA NPs before and after lyophilization are similar (n = 3 independent batches; mean ± SD).
Fig. 1 Polymer structure and NP characterization. (A) Cationic 1-(3-aminopropyl)-4-methyl-piperazine endcapped poly(1,4-butanediol-diacrylate-co-5-amino-1-pentanol) (named PBAE 457) is used to electrostatically self-assemble with plasmid DNA (pDNA) to form nonviral gene delivery NPs. (B) Hydrodynamic diameter and zeta potential of 457/DNA NPs before and after lyophilization are similar (n = 3 independent batches; mean ± SD).CC BY-NC · PubMed Central
Fig. 2 Widespread expression of GFP in retina and RPE 2 months after suprachoroidal injection of NPs containing a CMV-GFP expression plasmid. Brown Norway rats were given a 3-μl suprachoroidal injection of PBAE NPs containing 1 μg of CMV-GFP expression plasmid 1 mm posterior to the limbus in the inferonasal quadrant near the vertical meridian (A). Two months after injection, rats were euthanized, eyes were frozen in embedding medium, and transverse sections were immunohistochemically stained for GFP, counterstained with Hoechst, and merged with its fluorescent image. In the inferior (B), temporal (C), superior (D), and nasal (E) meridians of a section 600 μm posterior to the limbus through anterior retina [intersections of inner surface of blue ring and white lines in (A)], there was colocalization of fluorescence with anti-GFP staining in RPE and photoreceptor inner and outer segments. At the inferior (F), temporal (G), superior (H), and nasal (I) meridians of a section 1800 μm posterior to the limbus through posterior retina, staining for GFP in RPE and photoreceptor inner and outer segments was similar to that seen in anterior retina. Occasional weak expression of GFP was seen in cells of the inner retina (arrows). Scale bar, 100 μm.
Fig. 2 Widespread expression of GFP in retina and RPE 2 months after suprachoroidal injection of NPs containing a CMV-GFP expression plasmid. Brown Norway rats were given a 3-μl suprachoroidal injection of PBAE NPs containing 1 μg of CMV-GFP expression plasmid 1 mm posterior to the limbus in the inferonasal quadrant near the vertical meridian (A). Two months after injection, rats were euthanized, eyes were frozen in embedding medium, and transverse sections were immunohistochemically stained for GFP, counterstained with Hoechst, and merged with its fluorescent image. In the inferior (B), temporal (C), superior (D), and nasal (E) meridians of a section 600 μm posterior to the limbus through anterior retina [intersections of inner surface of blue ring and white lines in (A)], there was colocalization of fluorescence with anti-GFP staining in RPE and photoreceptor inner and outer segments. At the inferior (F), temporal (G), superior (H), and nasal (I) meridians of a section 1800 μm posterior to the limbus through posterior retina, staining for GFP in RPE and photoreceptor inner and outer segments was similar to that seen in anterior retina. Occasional weak expression of GFP was seen in cells of the inner retina (arrows). Scale bar, 100 μm.CC BY-NC · PubMed Central
Fig. 3 Time course of GFP expression after suprachoroidal injection of NPs containing a CMV-GFP expression plasmid. Brown Norway rats were given suprachoroidal, intravitreous, or subretinal injection of PBAE NPs containing 1 μg of CMV-GFP expression plasmid. Ocular sections immunohistochemically stained for GFP (Hoechst counterstain) merged with fluorescent image showed GFP in photoreceptor inner and outer segments and RPE 2 weeks (A), 1 month (B), 2 months (C), 4 months (D), and 6 months (E) after vector injection. Low magnification showed GFP fluorescence around the entire circumference of the eye (F). ELISA showed high levels of GFP in retina and RPE/choroid from 2 weeks to 8 months (last time point measured). (G). GFP was undetectable in retina and RPE/choroid 2 weeks after intravitreous injection of PBAE NPs, but there were high levels 2 weeks and 1 month after subretinal injection (H). Compared with eyes given a single suprachoroidal injection of PBAE NPs containing 1 μg of CMV-GFP, those given three injections had significantly higher levels of GFP in retina, but not RPE/choroid (I). *P = 0.018 by two-sample t test with equal variance for comparison with corresponding single injection control.
Fig. 3 Time course of GFP expression after suprachoroidal injection of NPs containing a CMV-GFP expression plasmid. Brown Norway rats were given suprachoroidal, intravitreous, or subretinal injection of PBAE NPs containing 1 μg of CMV-GFP expression plasmid. Ocular sections immunohistochemically stained for GFP (Hoechst counterstain) merged with fluorescent image showed GFP in photoreceptor inner and outer segments and RPE 2 weeks (A), 1 month (B), 2 months (C), 4 months (D), and 6 months (E) after vector injection. Low magnification showed GFP fluorescence around the entire circumference of the eye (F). ELISA showed high levels of GFP in retina and RPE/choroid from 2 weeks to 8 months (last time point measured). (G). GFP was undetectable in retina and RPE/choroid 2 weeks after intravitreous injection of PBAE NPs, but there were high levels 2 weeks and 1 month after subretinal injection (H). Compared with eyes given a single suprachoroidal injection of PBAE NPs containing 1 μg of CMV-GFP, those given three injections had significantly higher levels of GFP in retina, but not RPE/choroid (I). *P = 0.018 by two-sample t test with equal variance for comparison with corresponding single injection control.CC BY-NC · PubMed Central
Fig. 4 Nonviral suprachoroidal gene transfer of Vegf causes subretinal NV progressing to subretinal fibrosis. Rats were given suprachoroidal injection of PBAE NPs containing 1 μg of pVEGF. After 4 weeks, FA showed subretinal hyperfluorescence (A and B) (arrows) and leakage from retinal vessels (arrowhead). After 8 weeks, subretinal hyperfluorescence (C) (arrows) spread over a minute (D) (arrows), indicating leakage from subretinal NV. After 5 months, there was subretinal fibrosis (E and F) that stained with fluorescein (G and H) (arrows). An eye injected with control vector showed normal fundus (I) and FA (J). Four-month-old rho/VEGF mouse (K) showed new vessels from deep capillaries (arrows) to subretinal space (arrowheads; DyLight 594–conjugated GSA). Four months after suprachoroidal injection of NPs containing 1 μg of pVEGF, new vessels extended from deep capillaries to severe subretinal NV (L) and, in another eye, showed severe NV with disrupted retina (M) (fluorescein isothiocyanate GSA). Two weeks after suprachoroidal injection of 1 μg of pVEGF in NP, ELISA showed significantly higher VEGF in retina or RPE/choroid versus controls (N) (n = 8 NPs and n = 6 controls). *P < 0.0001 for retina and for RPE/choroid by two-sample t test with unequal variance for comparison with control. Scale bar, 200 μm.
Fig. 4 Nonviral suprachoroidal gene transfer of Vegf causes subretinal NV progressing to subretinal fibrosis. Rats were given suprachoroidal injection of PBAE NPs containing 1 μg of pVEGF. After 4 weeks, FA showed subretinal hyperfluorescence (A and B) (arrows) and leakage from retinal vessels (arrowhead). After 8 weeks, subretinal hyperfluorescence (C) (arrows) spread over a minute (D) (arrows), indicating leakage from subretinal NV. After 5 months, there was subretinal fibrosis (E and F) that stained with fluorescein (G and H) (arrows). An eye injected with control vector showed normal fundus (I) and FA (J). Four-month-old rho/VEGF mouse (K) showed new vessels from deep capillaries (arrows) to subretinal space (arrowheads; DyLight 594–conjugated GSA). Four months after suprachoroidal injection of NPs containing 1 μg of pVEGF, new vessels extended from deep capillaries to severe subretinal NV (L) and, in another eye, showed severe NV with disrupted retina (M) (fluorescein isothiocyanate GSA). Two weeks after suprachoroidal injection of 1 μg of pVEGF in NP, ELISA showed significantly higher VEGF in retina or RPE/choroid versus controls (N) (n = 8 NPs and n = 6 controls). *P < 0.0001 for retina and for RPE/choroid by two-sample t test with unequal variance for comparison with control. Scale bar, 200 μm.CC BY-NC · PubMed Central
Fig. 5 Effect of suprachoroidal or subretinal injection of NPs containing a VEGF-neutralizing protein expression plasmid. There was a significant increase in sFlt1 retinal protein 1 month after suprachoroidal injection of PBAE NPs containing 1 μg of p3sFlt1Fc (A) (n = 5; *P = 0.043 by Wilcoxon signed-rank test). Two weeks after suprachoroidal injection of 1 μg of p3sFlt1Fc in NPs (one eye) and 1 μg of pCMV-Luc in NP (other eye), 100 ng of VEGF165 was injected into both eyes. After 12 hours, Evans Blue assay showed significantly less dye leakage in p3sFlt1Fc-injected eyes (B) (n = 7; *P = 0.011 by paired t test). At P14, rho/VEGF mice were given subretinal injection of 1 μg of p3sFlt1Fc in NP (one eye) and 1 μg of pCMV-Luc in NP (other eye). At P35 (n = 8), RPE/choroid flat mounts stained with DyLight 594–labeled GSA showed red dots throughout control flat mounts (C) seen to be subretinal neovascularization (NV) by magnification (C) (upper right), which was decreased in sFlt1 NP-injected eyes (D) (magnified box, lower left). The mean area of NV per flat mount was significantly less in the p3sFlt1Fc NP group (E) (*P = 0.025 by Wilcoxon signed-rank test). This difference was maintained at P70 (F to H) (n = 6; *P = 0.046 by Wilcoxon signed-rank test).
Fig. 5 Effect of suprachoroidal or subretinal injection of NPs containing a VEGF-neutralizing protein expression plasmid. There was a significant increase in sFlt1 retinal protein 1 month after suprachoroidal injection of PBAE NPs containing 1 μg of p3sFlt1Fc (A) (n = 5; *P = 0.043 by Wilcoxon signed-rank test). Two weeks after suprachoroidal injection of 1 μg of p3sFlt1Fc in NPs (one eye) and 1 μg of pCMV-Luc in NP (other eye), 100 ng of VEGF165 was injected into both eyes. After 12 hours, Evans Blue assay showed significantly less dye leakage in p3sFlt1Fc-injected eyes (B) (n = 7; *P = 0.011 by paired t test). At P14, rho/VEGF mice were given subretinal injection of 1 μg of p3sFlt1Fc in NP (one eye) and 1 μg of pCMV-Luc in NP (other eye). At P35 (n = 8), RPE/choroid flat mounts stained with DyLight 594–labeled GSA showed red dots throughout control flat mounts (C) seen to be subretinal neovascularization (NV) by magnification (C) (upper right), which was decreased in sFlt1 NP-injected eyes (D) (magnified box, lower left). The mean area of NV per flat mount was significantly less in the p3sFlt1Fc NP group (E) (*P = 0.025 by Wilcoxon signed-rank test). This difference was maintained at P70 (F to H) (n = 6; *P = 0.046 by Wilcoxon signed-rank test).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 63

Metadata

Authors
Shen, J., Kim, J., Tzeng, S. Y., Ding, K., Hafiz, Z., Long, D., Wang, J., Green, J. J., & Campochiaro, P. A.
Affiliations
Johns Hopkins University (US)
Corresponding author
  • Green, Jordan J.
  • Campochiaro, Peter A.
Venue
Science Advances
Published
2020-07-03
Volume
6
Issue
27
ISSN
2375-2548 (ISSN-L)
OpenAlex
W3039061026
Cited by
63
References
40
Citations by year
2026: 7 · 2025: 11 · 2024: 7 · 2023: 12 · 2022: 9 · 2021: 13 · 2020: 4
FWCI
3.08
Type
journal article
Language
en
Open access
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (R21EY026148, R01EY028996, R01EB022148)
  • National Eye Institute (EY01765, RO1EY031097)
  • Research to Prevent Blindness
  • James and Carole Free Catalyst Award
  • Barth Foundation (none)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
biodegradable nanoparticles, subretinal injection, vascular endothelial growth factor, neovascular age-related macular degeneration, subretinal neovascularization, subretinal fibrosis, photoreceptors, retinal pigment epithelium, reporter plasmid, vascular leakage

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.